

simultaneously with the Attorney General and the Federal Trade Commission disclosing a change in membership of the Durability Validation of Composite NGV Fuel Cylinders Program, and correcting an error in the last notice published. The notification was filed for the purpose of extending the Act's provisions limiting the recovery of antitrust plaintiffs to actual damages under specified circumstances. Specifically, Southern California Gas Company, Los Angeles, CA, has become a party to the group research project. Further, in the title of the August 31, 1994 notice published at 59 FR 45013, the word "Valuation" should read "Validation".

No other changes have been made in either the membership or planned activity of the group research project. Membership in the project remains open, and SwRI intends to file additional written notification disclosing all changes in membership.

On July 12, 1994, SwRI filed its original notification pursuant to Section 6(a) of the Act. The Department of Justice published a notice in the **Federal Register** pursuant to Section 6(b) of the Act on August 31, 1994, 59 FR 45013.

Constance K. Robinson,

Director of Operations, Antitrust Division.

[FR Doc. 95-6196 Filed 3-13-95; 8:45 am]

BILLING CODE 4410-01-M

Notice Pursuant to the National Cooperative Research and Production Act of 1993—Processes for the Production of Steel From Iron Carbide and Related Technologies

Notice is hereby given that, on January 5, 1995, pursuant to Section 6(a) of the National Cooperative Research and Production Act of 1993, 15 U.S.C. 4301 *et seq.* ("the Act"), the parties to a cooperative research and production venture relating to processes for the production of steel from iron carbide and related technologies has filed a notification simultaneously with the Attorney General and the Federal Trade Commission disclosing (1) the identities of the parties and (2) the nature and objectives of the venture. The notifications were filed for the purpose of invoking the Act's provisions limiting the recovery of antitrust plaintiffs to actual damages under specified circumstances. Pursuant to Section 6(b) of the Act, the identities of the parties are: U.S. Steel Group, a unit of USX Corporation, Pittsburgh, PA; Nucor Corporation, Charlotte, NC; and Praxair, Inc., Danbury, CT. None of the parties are controlled by any other person. The nature and objectives of the venture are

to jointly conduct a feasibility study of a specific process for producing low-carbon alloys (steel) from iron carbide (the "Process"). If the feasibility study is successful, the venture will design, construct and operate a plant to demonstrate the feasibility of the Process (the "Demonstration Plant").

The venture will involve the testing of steel produced at the plant; the collection, exchange and analysis of research and production data and information obtained from operating the plant and concerning the Process, the iron carbide processed and steel produced at the plant; improvements and modifications to the Process; and development of related processes for the production of steel from iron carbide. The venture will also prosecute patent applications (domestic and foreign) covering the Process, improvements and related processes, and will hold title to such patents. The venture will license its patents and unpatented technology to third persons.

The parties have executed a Letter of Intent, dated as of October 5, 1994, which contemplates that they will enter into a written definitive agreement concerning the venture. No written definitive agreement has yet been executed.

Constance K. Robinson,

Director of Operations, Antitrust Division.

[FR Doc. 95-6195 Filed 3-13-95; 8:45 am]

BILLING CODE 4410-01-M

Drug Enforcement Administration

Manufacturer of Controlled Substances; Notice of Registration

By Notice dated November 21, 1994, and published in the **Federal Register** on November 29, 1994, (59 FR 61002), Isotec, Inc., 3858 Benner Road, Miamisburg, Ohio 45342, made application to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the basic classes of controlled substances listed below:

Drug	Schedule
Cathinone (1235)	I
Methcathinone (1237)	I
N-Ethylamphetamine (1475)	I
N,N-Dimethylamphetamine (1480)	I
Aminorex (1585)	I
Methaqualone (2565)	I
Lysergic acid diethylamide (7315)	I
Tetrahydrocannabinols (7370)	I
Mescaline (7381)	I
2,5-Dimethoxyamphetamine (7396)	I
3,4-Methylenedioxyamphetamine (7400)	I
3,4-Methylenedioxy-N-ethylamphetamine (7404)	I

Drug	Schedule
3,4-Methylenedioxy-methamphetamine (7405)	I
4-Methoxyamphetamine (7411)	I
N-Ethyl-1-phenylcyclohexylamine (7455)	I
Dihydromorphine (9145)	I
Normorphine (9313)	I
Acetylmethadol (9601)	I
Alphacetylmethadol Except Levo-Alphacetylmethadol (9603)	I
Normethadone (9635)	I
3-Methylfentanyl (9813)	I
Amphetamine (1100)	II
Methamphetamine (1105)	II
Methylphenidate (1724)	II
Amobarbital (2125)	II
Pentobarbital (2270)	II
Secobarbital (2315)	II
1-Phenylcyclohexylamine (7460)	II
Phencyclidine (7471)	II
Phenylacetone (8501)	II
1-Piperidinocyclohexanecarbonitrile (8603)	II
Codeine (9050)	II
Dihydrocodeine (9120)	II
Oxycodone (9143)	II
Hydromorphone (9150)	II
Benzoyllecgonine (9180)	II
Ethylmorphine (9190)	II
Hydrocodone (9193)	II
Isomethadone (9226)	II
Meperidine (9230)	II
Methadone (9250)	II
Methadone intermediate (9254)	II
Dextropropoxyphene, bulk (non-dosage forms) (9273)	II
Morphine (9300)	II
Levo-Alphacetylmethadol (9648)	II
Oxymorphone (9652)	II
Fentanyl (9801)	II

Comments were filed by two registered manufacturers. The comments were considered, however, DEA determined that the application should be approved. Therefore, pursuant to Section 303 of the Comprehensive Drug Abuse Prevention and Control Act of 1970 and Title 21, Code of Federal Regulations, Deputy Assistant Administrator, Office of Diversion Control, Deputy Assistant Administrator, Office of Diversion Control, hereby orders that the application submitted by the above firm for registration as a bulk manufacturer of the basic classes of controlled substances listed above is approved and registration is granted.

Dated: March 8, 1995.

Gene R. Haislip,

Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.

[FR Doc. 95-6218 Filed 3-13-95; 8:45 am]

BILLING CODE 4410-09-M